Acute Onset of Anemia After IV Immunoglobulin

Abstract

Get full access to this article

View all access options for this article.

References

Nydegger

Sturzenegger

. Adverse effects of intravenous immunoglobulin therapy. Drug Saf. 1999;21:171-185.

Dalakas

. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44:223-226.

Sekul

Cupler

Dalakas

. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121:259-262.

Dalakas

. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology. 1998;51(6, suppl 5):S2-S8.

Sakem

Matozan

Nydegger

Weigel

Griesmacher

Risch

. Anti-red blood cell antibodies, free light chains, and antiphospholipid antibodies in intravenous immunoglobulin preparations. Isr Med Assoc J. 2013;15:617-621.

US Food and Drug Administration. Vaccines, blood and biologics: immune globulin intravenous (IGIV) indications. http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm133691.htm. Accessed December 20, 2013.